Antihyperlipidemic agent.
Pharmacology: Gemfibrozil is a lipid-regulating agent which lowers elevated serum lipids primarily by decreasing serum triglycerides and total serum cholesterol. It reduces elevated plasma concentrations of triglycerides and to a somewhat smaller extent, elevated plasma concentrations of cholesterols, the effect is particularly evident in a reduction of elevated concentrations of very low density lipoproteins. It is also recommended by the American Diabetes Association for type II B dyslipidemias ie, high triglycerides, high LDL, low HDL as first-line therapy.
Treatment of hyperlipidemia. Lipigem has been used in long-term treatment and prophylaxis of patients with coronary heart disease.
Usual Dose: 0.6-1.2 g daily in divided doses.
Lipigem should not be given to patients with impaired liver and kidney function or with primary biliary cirrhosis. It should not be given during pregnancy.
Lipigem is contraindicated during pregnancy.
There have been occasional reports of nausea, vomiting, abdominal pain, anorexia, heartburn and diarrhea. Drowsiness, allergy and elevation of serum creatine kinase values have also been reported.
Anticoagulants, lovastatin.
Store at room temperature.
C10AB04 - gemfibrozil ; Belongs to the class of fibrates. Used in the treatment of hyperlipidemia.
Lipigem cap 300 mg
100's (P1,500/pack)
Sign Out
